RANKL-IN-2

Overview

RANKL-IN-2 is an orally active RANKL inhibitor with K d values of 3.21 μM and 4.625 μM in the SPR and MST assays, respectively. RANKL-IN-2 binds to RANKL to interfere with RANKL-RANK interaction. RANKL-IN-2 suppresses osteoclastogenesis by inhibiting ROS , MAPK and NF-κB pathways. RANKL-IN-2 inhibits osteoclastogenesis via inhibition of RANKL-induced osteoclast formation, bone resorption, and osteoclast-specific gene and protein expressions in vitro .RANKL-IN-2 prevents bone loss in ovariectomized osteoporosis mice.RANKL-IN-2 can be used for the research of osteoporosis.

Application

Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Mineral Metabolism | Products > Disease Areas > Osteoporosis | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > RANKL/RANK | Products > Signaling Pathways > Reactive Oxygen Species (ROS) | Products > Signaling Pathways > p38 MAPK | Products > Signaling Pathways > NF-κB

Product Information

• Catalog No.: HY-181079
• CAS No.: 2667022-87-7
• Molecular Formula: C17H13BrN2OSe
• Molecular Weight: 420.16
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source